Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $292,813.43 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Viviane Monges sold 9,667 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.29, for a total transaction of $292,813.43. Following the transaction, the director directly owned 5,500 shares in the company, valued at $166,595. This trade represents a 63.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Pharvaris Trading Up 1.3%

Shares of PHVS stock opened at $29.86 on Friday. Pharvaris N.V. has a 1 year low of $15.51 and a 1 year high of $33.33. The firm’s fifty day simple moving average is $28.72 and its 200 day simple moving average is $27.07. The firm has a market capitalization of $1.95 billion, a P/E ratio of -9.39 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities research analysts anticipate that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP acquired a new stake in shares of Pharvaris in the 3rd quarter valued at $43,282,000. Paradigm Biocapital Advisors LP boosted its stake in shares of Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after purchasing an additional 772,583 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Pharvaris in the 3rd quarter valued at $15,613,000. Commodore Capital LP boosted its stake in shares of Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after purchasing an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Citizens Jmp cut their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Wedbush boosted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. UBS Group set a $74.00 price target on shares of Pharvaris in a report on Wednesday, May 13th. Finally, Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.